GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Fact checked by Nick Blackmer With anti-obesity medications like Ozempic, Wegovy, and Zepbound exploding in popularity in ...

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.” ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...